Dianthus Therapeutics (DNTH) Common Equity: 2017-2025
Historic Common Equity for Dianthus Therapeutics (DNTH) over the last 7 years, with Sep 2025 value amounting to $546.5 million.
- Dianthus Therapeutics' Common Equity rose 61.72% to $546.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $546.5 million, marking a year-over-year increase of 61.72%. This contributed to the annual value of $352.5 million for FY2024, which is 108.73% up from last year.
- According to the latest figures from Q3 2025, Dianthus Therapeutics' Common Equity is $546.5 million, which was up 80.30% from $303.1 million recorded in Q2 2025.
- In the past 5 years, Dianthus Therapeutics' Common Equity ranged from a high of $546.5 million in Q3 2025 and a low of -$61.5 million during Q2 2023.
- For the 3-year period, Dianthus Therapeutics' Common Equity averaged around $257.7 million, with its median value being $328.6 million (2025).
- In the last 5 years, Dianthus Therapeutics' Common Equity plummeted by 145.30% in 2023 and then skyrocketed by 833.35% in 2024.
- Quarterly analysis of 4 years shows Dianthus Therapeutics' Common Equity stood at -$44.4 million in 2022, then spiked by 480.61% to $168.9 million in 2023, then skyrocketed by 108.73% to $352.5 million in 2024, then spiked by 61.72% to $546.5 million in 2025.
- Its Common Equity was $546.5 million in Q3 2025, compared to $303.1 million in Q2 2025 and $328.6 million in Q1 2025.